Synmosa Biopharma Corporation (4114.TWO)
TWD 33.45
(0.0%)
TWD 33.45
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.14 Billion | 4.38 Billion | 3.23 Billion | 3.03 Billion | 2.67 Billion |
| Cost of Revenue | 3.02 Billion | 2.55 Billion | 1.94 Billion | 1.9 Billion | 1.9 Billion |
| Gross Profit | 2.11 Billion | 1.82 Billion | 1.28 Billion | 1.13 Billion | 775.97 Million |
| Operating Expenses | 1.49 Billion | 1.37 Billion | 1.1 Billion | 1.01 Billion | 882.67 Million |
| Selling, General and Administrative Expenses | 1.29 Billion | 1.14 Billion | 883.58 Million | 817.24 Million | 671.13 Million |
| Research and Development Expenses | 210.9 Million | 215.28 Million | 214.37 Million | 159.52 Million | 211.54 Million |
| Other Expenses | 2.06 Million | 344.93 Million | 36.64 Million | 256.11 Million | - |
| Cost and Expenses | 4.52 Billion | 3.93 Billion | 3.04 Billion | 2.91 Billion | 2.78 Billion |
| Operating Income | 614.74 Million | 788 Million | 207.68 Million | 376.2 Million | -106.7 Million |
| Interest Expense | 67.25 Million | 59.58 Million | 51.97 Million | 52.82 Million | 54.36 Million |
| Income Tax Expense | 196.38 Million | 106.12 Million | 37.81 Million | 23.04 Million | -1.95 Million |
| Earnings before Tax | 601.55 Million | 725.01 Million | 153.88 Million | 497.64 Million | -132.76 Million |
| Net Income | 594.83 Million | 799.09 Million | 303.86 Million | 638.11 Million | 47.09 Million |
| Earnings Per Share Basic | 1.46 | 2.25 | 0.84 | 1.99 | 0.13 |
| Earnings Per Share Diluted | 1.61 | 2.24 | 0.83 | 1.99 | 0.13 |
| Weighted Average Shares Outstanding | 406.75 Million | 355.48 Million | 361.59 Million | 320.26 Million | 354.69 Million |
| Weighted Average Shares Outstanding (Diluted) | 370.46 Million | 356.67 Million | 362.79 Million | 321.83 Million | 355.12 Million |
| Gross Margin | 0.41 | 0.42 | 0.40 | 0.37 | 0.29 |
| EBIT Margin | 0.20 | 0.25 | 0.16 | 0.22 | 0.07 |
| Profit Margin | 0.12 | 0.18 | 0.09 | 0.21 | 0.02 |
| EBITDA | 1 Billion | 1.1 Billion | 524.31 Million | 678.35 Million | 183.79 Million |
| Earnings Before Tax Margin | 0.12 | 0.18 | 0.06 | 0.12 | -0.04 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 1.33 Billion | 1.28 Billion | 1.33 Billion | 5.14 Billion | 1.23 Billion | 1.31 Billion |
| Cost of Revenue | 756.2 Million | 713.58 Million | 787.17 Million | 3.02 Billion | 725.96 Million | 760.35 Million |
| Gross Profit | 576.47 Million | 567.91 Million | 550.28 Million | 2.11 Billion | 508.25 Million | 550.74 Million |
| Operating Expenses | 388.21 Million | 393.01 Million | 382.67 Million | 1.49 Billion | 369.9 Million | 370.72 Million |
| Selling, General and Administrative Expenses | 330.79 Million | 328.24 Million | 322.76 Million | - | 319.53 Million | 323.28 Million |
| Research and Development Expenses | 57.42 Million | 64.52 Million | 57.84 Million | - | 50.37 Million | 47.43 Million |
| Other Expenses | 17.79 Million | 26.09 Million | 8.81 Million | 53.93 Million | 8.95 Million | 31.64 Million |
| Cost and Expenses | 1.14 Billion | 1.1 Billion | 1.16 Billion | 4.52 Billion | 1.09 Billion | 1.13 Billion |
| Operating Income | 208.09 Million | 200 Million | 177.69 Million | 675.35 Million | 146.81 Million | 213.09 Million |
| Interest Expense | 14.51 Million | 14.3 Million | 14.49 Million | 67.25 Million | 14.87 Million | 19.32 Million |
| Income Tax Expense | 46.68 Million | 44.02 Million | 45.32 Million | 196.38 Million | 42.63 Million | 69.63 Million |
| Earnings before Tax | 193.71 Million | 185.31 Million | 157.82 Million | 601.55 Million | 133.15 Million | 192.81 Million |
| Net Income | 202.36 Million | 181.58 Million | 170.69 Million | 594.83 Million | 134.44 Million | 163.62 Million |
| Earnings Per Share Basic | 0.48 | 0.48 | 0.45 | - | 0.35 | 0.46 |
| Earnings Per Share Diluted | 0.48 | 0.47 | 0.45 | - | 0.35 | 0.46 |
| Weighted Average Shares Outstanding | 420.61 Million | 378.29 Million | 376.68 Million | 369.24 Million | 384.12 Million | 357.79 Million |
| Weighted Average Shares Outstanding (Diluted) | 420.61 Million | 386.34 Million | 377.29 Million | 370.46 Million | 384.12 Million | 357.79 Million |
| Gross Margin | 0.43 | 0.44 | 0.41 | 0.41 | 0.41 | 0.42 |
| EBIT Margin | 0.22 | 0.22 | 0.20 | - | 0.19 | 0.23 |
| Profit Margin | 0.15 | 0.14 | 0.13 | 0.12 | 0.11 | 0.12 |
| EBITDA | 293.41 Million | 286.01 Million | 263.47 Million | - | 232.09 Million | 299.33 Million |
| Earnings Before Tax Margin | 0.16 | 0.16 | 0.13 | 0.13 | 0.12 | 0.16 |
TARSONS
600210
6201
ADM
NDA
WEYS